Dr. Finn has twenty years of experience in the research, development and government regulation of biological and pharmaceutical products covering a wide range of product types and therapeutic indications. He brings unique expertise to Symphony Evolution, both as a regulatory expert and as a manager of successful product development teams.
Dr. Finn began his career as a Staff Fellow at FDA, Center for Biologics Evaluation and Research and then entered the product development industry where he has held senior positions of increasing responsibility in regulatory affairs and product development with several companies including Lederle-Praxis Biologicals, Miles Pharmaceuticals, Genetics Institute, BRI International, Quintiles, Prestwick Clinical and RRD International. During his career, Dr. Finn has worked on numerous successful biotech and pharmaceutical product development programs including Cipro IV®, HibTITER® (Haemophilus b Conjuagate Vaccine), Numega® (rhIL11), rhIL12, rhM-CSF, InFuse, and Arava® (leflunomide).
While at BRI, Dr. Finn established a regulatory affairs services group to provide contract regulatory services to biotechnology and pharmaceutical customers. After the merger of BRI and Quintiles, the scope of his responsibilities was expanded to include the management of product development activities. As Senior Vice President, he established and managed the business units responsible for providing contract services to customers with infectious diseases/immunology products, and to customers with allergy, respiratory, and dermatology products. Dr. Finn created a group of senior project managers who collectively had many years of successful experience managing Phase I through IV clinical programs. These managers were distinguished within Quintiles for their knowledge, experience and success in setting up and supervising sites, for their successful management of sites and site monitors, and for their timely delivery of high quality data and study reports.
For the previous six years Dr. Finn managed both product development and regulatory activities for Quintiles and most recently at Prestwick Clinical where he served as President prior to co-founding RRD International.